In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Hetero Drugs Ltd.

http://www.heterodrugs.com

Latest From Hetero Drugs Ltd.

Coronavirus Update: Gilead To Meet Global Remdesivir Demand By October

Ramp-up is possible thanks to increased internal capacity and network of voluntary licensing partners including Mylan, Cipla and Dr Reddy's.

Coronavirus COVID-19 Deals

Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study

Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints. 

Coronavirus COVID-19 Clinical Trials

India Remdesivir Black Market: Supply Gap May Normalize Soon, But No End To Greed

India generic remdesivir supply situation seen improving soon, with existing players Cipla and Hetero ramping up the antiviral and the arrival of new entrant Mylan. But will that be enough to control black marketing of the investigational COVID-19 therapy? The government is also keeping a close watch on the goings on.

India Coronavirus COVID-19

COVID-19: Gilead To Fill Remdesivir Supply Gap In EU

As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.

Europe International
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register